Salim Syed’s rating is based on a combination of encouraging developments surrounding CrisprTherapeuticsAG. Firstly, the pricing of Casgevy in Saudi Arabia appears to be around $2 million per ...
CRISPRTherapeuticsAG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports.
ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPRTherapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
PFG Investments LLC lessened its holdings in shares of CRISPRTherapeuticsAG (NASDAQ:CRSP – Free Report) by 7.3% during the third quarter, according to its most recent disclosure with the ...